Cytosorbents (CTSO) falls 0.13% in Light Trading on July 30 – Equities.com

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange

CTSO - Market Data & News

Cytosorbents Corp (NASDAQ: CTSO) shares fell 0.13%, or $0.01 per share, to close Friday at $7.61. After opening the day at $7.58, shares of Cytosorbents fluctuated between $7.75 and $7.58. 147,569 shares traded hands a decrease from their 30 day average of 296,122. Friday's activity brought Cytosorbentss market cap to $329,659,850.

Cytosorbents is headquartered in Monmouth Junction, New Jersey..

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb has been used in more than 110,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. CytoSorbents purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY, CytoSorb-XL, HemoDefend-RBC, HemoDefend-BGA, VetResQ, K+ontrol, ContrastSorb, DrugSorb, and others.

Visit Cytosorbents Corps profile for more information.

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Cytosorbents Corp and to follow the companys latest updates, you can visit the companys profile page here: Cytosorbents Corps Profile. For more news on the financial markets be sure to visit Equities News. Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Follow this link:
Cytosorbents (CTSO) falls 0.13% in Light Trading on July 30 - Equities.com